Objectives: We report herein the clinical, histological, and immunohistochemical features of a case of sarcomatoid chromophobe renal cell carcinoma.
Methods/results: A 59-year-old woman referred a two-month history of constant right flank pain, and hematuria. A right radical nephrectomy was performed. Gross pathologic examination showed a tumor located in the lower part of the kidney with two different aspects. Histologically, the tumor was composed of two intermixed distinct morphologic components: a chromophobe renal cell carcinoma and a high-grade spindle cell sarcoma.
Conclusion: Our case represent a typical sarcomatoid chromophobe cell carcinoma. This unusual renal cancer has the potential to behave aggressively and to metastasize.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4321/s0004-06142006000200018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary tumor characteristics and immunohistochemical profile of renal cell carcinoma in serous fluid cytology.
J Am Soc Cytopathol
November 2024
Cytopathology Center of Excellence, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Introduction: Renal cell carcinoma (RCC) involves serosal surfaces in 2%-3% of cases, and thus few papers describe serous fluid cytology (SFC) involvement by RCC. This diagnosis is challenging, given its rarity, nondescript cytomorphologic features and infrequent expression of widely used epithelial markers MOC31 and BerEP4. We describe our institutional experience with RCC in SFC specimens.
View Article and Find Full Text PDFPattern of care and treatment outcomes of metastatic non-clear cell kidney cancer: a single centre experience from India.
Ecancermedicalscience
September 2024
Uro-Surgery, Tata Medical Center, 14 MAR (EW), New Town, Rajarhat, Kolkata 700160, West Bengal, India.
Background: Non-clear-cell renal cell carcinoma (nccRCC) refers to a rare diverse heterogeneous group of tumours; usually treated with immune check point inhibitors and or tyrosine kinase inhibitors (TKIs). Prospective large-scale data from Asian countries is limited.
Methods: This is a retrospective study of patients with metastatic nccRCC treated at Tata Medical Centre, Kolkata, India, from 2012 to 2022.
Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation (osteosarcomatous and chondrosarcomatous differentiation)-A Case Report and Comprehensive Review.
J Kidney Cancer VHL
September 2024
Department of Urology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Chromophobe renal cell carcinomas (ChRCCs) have a good prognosis and comprise approximately 5-7% of renal cell carcinomas (RCCs). The sarcomatoid differentiation in RCC is found in around 5-10% of cases; however, in ChRCC, it is much less than in other RCCs and poorly responds to chemotherapeutic agents. A study by de Peralta-Venturina et al.
View Article and Find Full Text PDFMolecular Analysis of Renal/Adrenal Angiosarcomas Reveals High Frequency of Recurrent Genetic Alterations.
Genes Chromosomes Cancer
September 2024
Department of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Angiosarcomas of the kidney and adrenal gland are rare, highly aggressive vascular neoplasms. Their genomic profile has not been systematically studied to date. We report the clinicopathologic and molecular features of six angiosarcomas centered in the kidney/adrenal gland.
View Article and Find Full Text PDFEvaluation of American Urological Association Renal Cell Carcinoma Risk Groups for Chromophobe Renal Cell Carcinoma.
Urology
December 2024
Department of Urology, Mayo Clinic, Rochester, MN. Electronic address:
Objective: To develop and compare various models for risk stratification in chromophobe renal cell carcinoma (chrRCC). Models have been developed to predict progression-free (PFS) and cancer-specific survival (CSS) following surgery for localized renal cell carcinoma (RCC). Notably, chromophobe RCC (chrRCC) is not included in American Urological Association (AUA) risk stratification, as nuclear grading is not recommended.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!